Aprepitant

Limits on what this shows

• Key negative/null findings: No measurement of mitochondrial membrane potential, respiration or biogenesis in aprepitant-treated people or healthy tissue was located (PubMed listings: aprepitant AND mitochondria returned three records; aprepitant AND mitochondrial membrane potential returned no records).
• At-risk subgroups: None established.
• Counter-evidence on record: Cytotoxicity in cancer cells is the intended repurposing effect in that paper and is not a nutrient or mitochondrial-toxicity finding in patients. Aprepitant concentrations used were not retrieved.

Direction

Burden (cell toxicity) in malignant cells at experimental exposure; the opposite (protective) direction is suggested only by a title-level paper that could not be read.

Regulatory status

No mitochondrial statement in the label text read [1][2][3].

Population evidence

Tier B: Cancer Lett 2026 reported that aprepitant activated mitochondria-dependent necroptosis in relapsed/refractory acute lymphoblastic leukemia cells, with ER calcium discharge, mitochondrial calcium accumulation, oxidative stress and mitochondrial fragmentation, and tumor suppression in xenografts [9]. A 2026 Daru paper in Wistar rats is titled as aprepitant neuroprotection against methylphenidate-induced biochemical/mitochondrial dysfunction; only title and metadata were retrieved (abstract unavailable), so its findings are not used [15]. A Liver Int 2024 cholangiocarcinoma paper (ROS/JNK, autophagy and apoptosis) was found by title; its abstract fetch was rate-limited and not retried [17].

Mechanism

Named for [9]: calcium-mediated mitochondrial stress leading to RIP1/RIP3/MLKL necroptosis. Not shown in non-malignant human cells.

Counter-evidence held on record

Framing caution for the consumer surface A cell-culture cancer result; it does not indicate mitochondrial damage in people taking aprepitant for nausea, and no supplement is implied.

Limits on what this shows

• Key negative/null findings: No human study measuring MDA, glutathione, total antioxidant capacity or similar in aprepitant-treated people was located. Several further aprepitant redox papers (cisplatin nephrotoxicity and hepatotoxicity 2020; vancomycin kidney injury with GPX4/system Xc- 2025; methylphenidate rat model 2026; prostate cancer cells with hesperidin 2023) were found by title or metadata only, their abstracts were not available, and they are not used as evidence [13][14][15][16].
• At-risk subgroups: None established; all models are cells or rodents under inflammatory, toxic or malignant conditions.
• Counter-evidence on record: The same drug is protective in one model and pro-oxidant in another, so no single direction can be stated. Whether experimental concentrations resemble human plasma exposure could not be assessed from the abstracts read.

Direction

Mixed: antioxidant-direction in LPS-stimulated macrophages and in substance P-stimulated glioblastoma cells; pro-oxidant in acute lymphoblastic leukemia cells (an intended anticancer repurposing effect, not a nutrient finding, Hard Rule 2).

Regulatory status

No oxidative-stress or antioxidant statement in the label text read [1][2][3].

Population evidence

Tier B, aprepitant as the test article in each: (a) LPS-treated RAW264.7 macrophages: aprepitant reduced ROS generation and NOX-4 expression and suppressed cytokine secretion through NF-kB inhibition; MDA, ROS and nitric oxide were measured (Drug Des Devel Ther 2020) [7]. (b) U87 glioblastoma cells: substance P/NK1R activation raised malondialdehyde and ROS and lowered thiols and total antioxidant capacity; aprepitant reversed these (BioMed Res Int 2022) [8]. (c) Relapsed/refractory acute lymphoblastic leukemia cells and xenografts: aprepitant triggered endoplasmic reticulum calcium release, mitochondrial calcium accumulation, oxidative stress elevation and mitochondrial fragmentation, leading to necroptosis; reducing oxidative stress diminished the cytotoxicity (Cancer Lett 2026) [9]. Abstracts only, reconstructed through OpenAlex; concentrations were not retrieved.

Mechanism

Named: NK1R blockade lowering NADPH oxidase 4 and NF-kB signaling in macrophages [7]; restoration of thiol and total antioxidant capacity in glioblastoma cells [8]; calcium-driven mitochondrial oxidative stress in leukemia cells [9].

Counter-evidence held on record

Framing caution for the consumer surface Laboratory findings only; they do not show that aprepitant lowers or raises antioxidant status in people. No antioxidant supplement is implied.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C source on aprepitant (or fosaprepitant) and copper was located, and no circulating claim linking aprepitant to copper was found to rebut as white. This is a disclosed evidence gap, not a finding of safety.

Channels tried

Labels [1][2][3]: no copper text (the capsule extract was asked specifically about iron, copper and nutrient statements and reported none). PubMed listing "aprepitant AND (copper OR ceruloplasmin)": seven records, all antiemetic pharmacology papers in chicks, ferrets or in silico models (several use copper sulfate only as an emetic stimulus), none measuring copper status in aprepitant-exposed subjects; titles only. RxList and Drugs.com pages [5][6]: no copper content. OpenAlex search endpoint and Europe PMC: HTTP 429, not retried. Repair pass 2026-10-04: current capsule label and a generic fosaprepitant label re-read through extraction for copper (not found) [1][24]; PubMed listing "(aprepitant OR fosaprepitant) AND (copper OR ceruloplasmin OR trace element)" returned seven records, all animal antiemetic-screening papers, one glioblastoma polypharmacy proposal and none measuring copper status in aprepitant-exposed subjects (titles only); Crossref bibliographic search and Semantic Scholar searches returned HTTP 429 or off-topic records.

Assessment

Mostly a genuine gap: two independent PubMed listing misses with different phrasing plus three label reads and two consumer-page reads. Residual tooling limits: bibliographic search endpoints (Europe PMC, OpenAlex search, Crossref, Semantic Scholar search) were rate-limited, so full-text mentions of copper cannot be excluded.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C source measured iron, ferritin, transferrin saturation, hepcidin or labile iron with aprepitant, and no circulating claim about aprepitant and iron was found. The one ferroptosis-themed paper (vancomycin kidney injury in rats, GPX4/system Xc-, 2025) is now read at abstract level [23]: aprepitant 20 mg/kg orally lowered renal system Xc- and GPX4 levels, raised catalase and GSH and lowered MDA, but no iron, ferritin, transferrin or labile-iron measurement is stated, and ferroptosis markers are not an iron measurement, so it cannot support even a yellow grade.

Channels tried

Labels [1][2][3]: no iron text (fosaprepitant extract searched for the words iron, hemoglobin and electrolyte: absent). PubMed listings: "aprepitant AND iron" returned four records (pruritus, a magnetic nanocomposite for drug release, and two head-and-neck supportive therapy reviews), none on iron status; "aprepitant AND ferroptosis" returned only the 2025 vancomycin paper. Crossref DOI record for that paper: no abstract. RxList [5]: no iron or mineral statements. Europe PMC and OpenAlex search 429. Repair pass 2026-10-04: WebSearch "aprepitant iron ferroptosis intracellular iron GPX4 cells" returned only generic ferroptosis pages and no aprepitant iron study; PubMed listing "(aprepitant OR fosaprepitant) AND (iron OR ferritin OR serum iron OR hemolysis)" returned five records (pruritus, head-and-neck supportive therapy reviews, a magnetic nanocomposite, a drug-product complaint analysis), none on iron status; current capsule and generic fosaprepitant labels re-read for iron and hemolysis (not found) [1][24]; the abstract of [14] was obtained through a Semantic Scholar single-DOI record [23].

Assessment

Mostly a genuine gap. The earlier residual uncertainty is resolved for the abstract: it reports no iron measurement. The full text of [14] was not opened and could contain iron staining or iron-content data not visible in the abstract; a later revision with full-text access should check it.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C source on aprepitant or fosaprepitant and gut microbiota was located, and no circulating claim about aprepitant and the microbiome was found. Constipation, diarrhea and hiccups are labeled drug effects, not microbiome evidence. The ondansetron and granisetron sibling findings are not borrowed: those are 5-HT3 antagonists, aprepitant (an NK1 antagonist) was not in their cohorts, and the cohort test fails.

Channels tried

PubMed listings: "aprepitant AND microbiota", "aprepitant AND dysbiosis", "aprepitant AND microbiome" and "fosaprepitant AND microbiota" each returned an HTTP 404 page, which on PubMed with this URL form appears to mean no matching records but was not confirmed by a visible zero-count; "aprepitant AND gut AND bacteria" was rate-limited (429) and not retried; "NK1 receptor antagonist AND gut microbiota" returned one fibromyalgia repurposing review (not a microbiome study); "aprepitant AND fecal" returned a rat/dog disposition paper, a gerbil colonic sensitivity paper and a mouse cryptosporidiosis paper, none a microbiome study. Crossref bibliographic search: no relevant hit. Europe PMC query: 429, not retried. Repair pass 2026-10-04: WebSearch "aprepitant gut microbiota mice 16S sequencing" and "aprepitant intestinal microbiota alteration chemotherapy patients or rats fecal microbiome NK1 antagonist" returned generic microbiota methods pages and chemotherapy microbiome papers, no aprepitant microbiome study; a third query (aprepitant AND gut microbiota/microbiome antiemetic) returned unrelated pages. PubMed listing "aprepitant microbiota" returned 404 again. Opened and cohort-checked: (a) Maier 2018 Nature drug-by-bacteria screen (more than 1,000 marketed drugs, 40 gut strains): aprepitant is not mentioned in the article text, and the per-drug supplementary table was not reachable, so whether aprepitant was screened is still unknown [26]; (b) an acupuncture-for-CINV rat study with 16S sequencing names aprepitant only as a network-pharmacology reference drug, and its rats received no aprepitant (cohort test fails) [27]; (c) an npj Breast Cancer study of baseline microbiome diversity and chemotherapy GI symptoms lists aprepitant among as-needed antiemetics but did not analyze antiemetics against microbiome composition (cohort test fails) [28]. A 2026 ovarian-cancer CINV gut-microbiota paper surfaced in search but its page was blocked by a reCAPTCHA and a PubMed fetch returned HTTP 429, so it was not opened and is not used [29].

Assessment

Probably a genuine gap but partly tooling-limited: the 404 pages are an indirect signal, the Maier supplementary table and the ovarian-cancer CINV microbiota paper were not reachable, and a later revision should check both for aprepitant-specific data.

Limits on what this shows

• Key negative/null findings: The text read for [21] reports no ATP, oxygen consumption or glycolysis measurement, no normal (non-malignant) cell line, no ROS-scavenger rescue and no cytochrome c release or Bax/Bcl-2 data. No aprepitant study measuring cellular ATP was located in PubMed listings ("aprepitant AND ATP"; "aprepitant AND (oxygen consumption OR bioenergetic OR energy metabolism OR ATP levels)"; Semantic Scholar and Crossref searches were rate-limited or unproductive). The methylphenidate rat paper titled as mitochondrial dysfunction has no retrievable abstract (publisher-elided in Semantic Scholar, null in OpenAlex) and is not used [15].
• At-risk subgroups: None established.
• Counter-evidence on record: Depolarization in a dying cancer cell cannot be separated, in the text read, from a downstream feature of cell death; the exposure range was not compared with human plasma exposure in the text read. Aprepitant also lowered oxidative damage markers and ferroptosis markers in a rat toxicity model and in macrophage and glioblastoma cells [7][8][23], so the direction depends on context.

Direction

Burden direction (possible reduced ATP-synthesis capacity) in malignant cells at experimental exposure. This is an intended anticancer repurposing effect, not a nutrient finding (Hard Rule 2).

Regulatory status

No ATP or energy-metabolism statement in the label text read [1][2][3][24]. Labeled fatigue is an adverse reaction in chemotherapy patients, not an ATP measurement.

Population evidence

Tier B, aprepitant as the test article: BMC Cancer 2023, GBC-SD and NOZ gallbladder cancer cells, aprepitant 6.25 to 100 uM (IC50 11.76 uM and 15.32 uM). After 60 minutes of aprepitant, JC-1 red fluorescence decreased and green fluorescence increased, read by the authors as depolarization of the mitochondrial membrane potential (not quantified in the text read); ROS generation was increased at 20 minutes; caspase-3 and caspase-9 activation was shown by Western blot; a nude-mouse xenograft (aprepitant 10 mg/kg every other day for 21 days) showed tumor inhibition [21]. Corroborating but abstract-only: Liver Int 2024 reported that aprepitant triggered mitochondria-dependent cell death through ROS/JNK signaling in intrahepatic cholangiocarcinoma cells, with antioxidant treatment completely preventing cytotoxicity; no membrane potential or ATP value is stated in that abstract [22]. Text for [21] was read through a summarizing fetch tool and for [22] through an OpenAlex record.

Mechanism

Partial: loss of mitochondrial membrane potential reduces the driving force for ATP synthase, but [21] did not test that step, and the ROS-driven signaling in [21][22] is the authors' proposed route to cell death.

Counter-evidence held on record

Framing caution for the consumer surface A cell-culture cancer result on a membrane-potential surrogate; ATP was not measured and nothing here shows reduced energy production in people taking aprepitant for nausea. No supplement is implied.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C source reports aprepitant effects on hemoglobin, hematocrit, red-cell mass, methemoglobin, arterial oxygenation or tissue oxygen delivery, and no circulating claim about oxygen-carrying capacity for aprepitant was found. Anemia is listed in the EMEND label as a less common reaction and hemoglobin decreased at 5% versus 4% on comparator in the pediatric chemotherapy table [1]; the fosaprepitant label lists anemia at 3% versus 2% in adult moderately emetogenic chemotherapy [24]. In these chemotherapy-treated patients the anemia and hemoglobin fall are overwhelmingly explained by myelosuppressive chemotherapy and cancer (confounding by indication, Hard Rule 6), and anemia is an outcome, not an iron or oxygen-delivery nutrient finding (Hard Rule 2) [1][2][5]. The one non-chemotherapy dataset located, the older repackager label summary of postoperative nausea and vomiting studies (564 patients on aprepitant 40 mg orally, 538 on ondansetron 4 mg IV), reports hemoglobin decreased in 3.8% versus 4.2%, the only laboratory adverse experience at 3% or more; this shows no excess over an active comparator, but it has no placebo arm, the perioperative setting (blood loss, fluids) confounds it, and it is a safety-table entry, not an oxygen-delivery study [3]. It is a documented null against a comparator, not evidence of safety or of an effect.

Channels tried

Labels [1][2][3]: anemia, febrile neutropenia and thrombocytopenia listed with chemotherapy-treated trial patients; fosaprepitant pediatric text lists anemia, neutropenia and thrombocytopenia as common reactions; no oxygenation text. PubMed listing "aprepitant AND hemoglobin": four records (intracerebral hematoma clearance in a mouse model, ifosfamide encephalopathy risk factors, and two head-and-neck supportive therapy reviews), none an oxygen-delivery study. PubMed listing "aprepitant AND (anemia OR methemoglobinemia OR hemolysis)": seven records, including a pediatric phase 3 trial (Lancet Oncol 2015) [18] whose abstract was null in OpenAlex and was not read, and sickle cell substance P papers not testing aprepitant for oxygen delivery. Queries listed in [19]. Repair pass 2026-10-04: label lab-abnormality tables re-read: the older repackager label HEC laboratory table lists proteinuria, ALT, BUN, creatinine and AST at 3% or more and no hemoglobin or hematocrit row, with neutropenia 3.1% versus 2.9% (HEC) and 5.8% versus 5.6% (MEC) [3]; the current capsule label has no hemolysis, hematocrit or iron text [1]; a generic fosaprepitant label has no hemolysis, hemoglobin, hematocrit or iron text, and its infusion-site reactions are local, not hemolytic [24]. WebSearch "fosaprepitant hemolysis infusion site reaction hemoglobin study" returned infusion-site-reaction incidence papers and labels only; those papers were not opened. PubMed listing "(aprepitant OR fosaprepitant) AND (iron OR ferritin OR serum iron OR hemolysis)" returned nothing relevant (see Iron).

Assessment

Mostly a genuine gap for oxygen delivery per se, with the labeled anemia handled as a chemotherapy-confounded outcome and the PONV hemoglobin figure recorded as a comparator-referenced null. Tooling-limited for the pediatric Lancet Oncol trial, whose adverse event table was not read, and for the fosaprepitant infusion-site reaction papers, which were not opened.